Suppr超能文献

了解成人囊性纤维化患者中的铜绿假单胞菌状况:利兹标准与临床医生决策的真实世界比较。

Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.

机构信息

School of Health and Related Research (ScHARR), University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.

Sheffield Adult Cystic Fibrosis Centre, Brearley Outpatient, Northern General Hospital, Herries Road, S5 7AU, Sheffield, UK.

出版信息

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):735-743. doi: 10.1007/s10096-017-3168-4. Epub 2018 Jan 6.

Abstract

Pseudomonas aeruginosa status influences cystic fibrosis (CF) clinical management but no 'gold standard' definition exists. The Leeds criteria are commonly used but may lack sensitivity for chronic P. aeruginosa. We compared clinicians' decision with the Leeds criteria in three adult CF centres. Two independent prospective datasets (Sheffield dataset, n = 185 adults; ACtiF pilot dataset, n = 62 adults from two different centres) were analysed. Clinicians involved in deciding P. aeruginosa status were blinded to the study objectives. Clinicians considered more adults with CF to have chronic P. aeruginosa infection compared to the Leeds criteria. This was more so for the Sheffield dataset (106/185, 57.3% with clinicians' decision vs. 80/185, 43.2% with the Leeds criteria; kappa coefficient between these two methods 0.72) compared to the ACtiF pilot dataset (34/62, 54.8% with clinicians' decision vs. 30/62, 48.4% with the Leeds criteria; kappa coefficient between these two methods 0.82). However, clinicians across different centres were relatively consistent once age and severity of lung disease, as indicated by the type of respiratory samples provided, were taken into account. Agreement in P. aeruginosa status was similar for both datasets among adults who predominantly provided sputum samples (kappa coefficient 0.78) or adults > 25 years old (kappa coefficient 0.82). Across three different centres, clinicians did not always agree with the Leeds criteria and tended to consider the Leeds criteria to lack sensitivity. Where disagreement occurred, clinicians tended to diagnose chronic P. aeruginosa infection because other relevant information was considered. These results suggest that a better definition for chronic P. aeruginosa might be developed by using consensus methods to move beyond a definition wholly dependent on standard microbiological results.

摘要

铜绿假单胞菌状态影响囊性纤维化(CF)的临床管理,但目前尚不存在“金标准”定义。利兹标准被广泛应用,但可能对慢性铜绿假单胞菌感染缺乏敏感性。我们在三个成人 CF 中心比较了临床医生的决策与利兹标准。分析了两个独立的前瞻性数据集(谢菲尔德数据集,n=185 名成人;ACtiF 试点数据集,n=来自两个不同中心的 62 名成人)。参与决定铜绿假单胞菌状态的临床医生对研究目标不知情。与利兹标准相比,临床医生认为更多的 CF 患者存在慢性铜绿假单胞菌感染。谢菲尔德数据集更为明显(106/185,临床医生决策为 57.3%,而利兹标准为 80/185,43.2%;这两种方法之间的kappa 系数为 0.72),而 ACtiF 试点数据集则不太明显(34/62,临床医生决策为 54.8%,而利兹标准为 30/62,48.4%;这两种方法之间的kappa 系数为 0.82)。然而,一旦考虑到年龄和肺部疾病的严重程度(由提供的呼吸道样本类型指示),不同中心的临床医生就相对一致。在主要提供痰样本的成年人(kappa 系数 0.78)或年龄大于 25 岁的成年人(kappa 系数 0.82)中,两个数据集的铜绿假单胞菌状态的一致性相似。在三个不同的中心,临床医生并不总是同意利兹标准,而且往往认为利兹标准缺乏敏感性。在出现分歧的情况下,临床医生往往会诊断为慢性铜绿假单胞菌感染,因为考虑到了其他相关信息。这些结果表明,可以通过使用共识方法来制定更好的慢性铜绿假单胞菌定义,从而超越完全依赖标准微生物学结果的定义。

相似文献

1
Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.
Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):735-743. doi: 10.1007/s10096-017-3168-4. Epub 2018 Jan 6.
3
Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.
Eur Respir J. 2006 May;27(5):937-43. doi: 10.1183/09031936.06.00100805.
6
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2020 Jun 10;6(6):CD009528. doi: 10.1002/14651858.CD009528.pub5.
7
Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.
Respir Care. 2014 Mar;59(3):363-70. doi: 10.4187/respcare.02549. Epub 2013 Aug 27.
9
Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.
Respirology. 2016 Feb;21(2):329-37. doi: 10.1111/resp.12714. Epub 2015 Dec 28.

引用本文的文献

1
Ecological patterns and processes of temporal turnover within lung infection microbiota.
Microbiome. 2024 Mar 25;12(1):63. doi: 10.1186/s40168-024-01780-6.
2
Nebuliser systems for drug delivery in cystic fibrosis.
Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3.
4
Digital technology for early identification of exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD014606. doi: 10.1002/14651858.CD014606.pub2.
5
Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
Cochrane Database Syst Rev. 2023 Mar 29;3(3):CD013766. doi: 10.1002/14651858.CD013766.pub2.
6
Role of Tobramycin in the Induction and Maintenance of Viable but Non-Culturable in an In Vitro Biofilm Model.
Antibiotics (Basel). 2020 Jul 10;9(7):399. doi: 10.3390/antibiotics9070399.
7
Impact of Coexistence Phenotype Between and Isolates on Clinical Outcomes Among Cystic Fibrosis Patients.
Front Cell Infect Microbiol. 2020 Jun 3;10:266. doi: 10.3389/fcimb.2020.00266. eCollection 2020.
8
Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis.
Curr Opin Pulm Med. 2019 Nov;25(6):636-645. doi: 10.1097/MCP.0000000000000616.
9
Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2219-2222. doi: 10.1007/s10096-018-3358-8. Epub 2018 Aug 18.

本文引用的文献

1
Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".
Patient Prefer Adherence. 2016 May 23;10:887-900. doi: 10.2147/PPA.S105530. eCollection 2016.
2
Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis.
J Cyst Fibros. 2016 Sep;15(5):605-10. doi: 10.1016/j.jcf.2016.01.001. Epub 2016 Jan 26.
3
How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.
J Hosp Infect. 2016 Jan;92(1):54-60. doi: 10.1016/j.jhin.2015.09.010. Epub 2015 Oct 8.
4
Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
Chest. 2016 Feb;149(2):390-400. doi: 10.1378/chest.15-0676. Epub 2016 Jan 12.
7
Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Clin Infect Dis. 2015 Mar 1;60(5):703-12. doi: 10.1093/cid/ciu944. Epub 2014 Nov 25.
9
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
Pediatr Pulmonol. 2015 Jan;50(1):42-8. doi: 10.1002/ppul.23036. Epub 2014 Mar 18.
10
Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review.
J Cyst Fibros. 2014 Sep;13(5):499-507. doi: 10.1016/j.jcf.2014.01.005. Epub 2014 Feb 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验